In this role, Dr Vickers will lead Resolvyx’s research and drug discovery activities, and will serve on the company’s management team. Dr Vickers will also join the Resolvyx board of directors.
Before joining Resolvyx, Dr Vickers was senior vice president and head of US research for Boehringer-Ingelheim.
Dr Vickers holds a PhD in biochemistry from the University of Toronto and a bachelor of science degree in applied biochemistry from the University of Salford, Manchester, England.
Paul Rubin, CEO of Resolvyx, said: “Phil brings more than two decades of experience leading drug discovery for world-class R&D operations, and his depth of knowledge will be highly valued as our team continues to advance our therapeutic programs.”